Multiple Myeloma Day

Multiple Myeloma Day

Mar 29, 2019

multiple myeloma day
Multiple Myeloma Day

Multiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information on  Multiple Myeloma.

Downloads

Article in PDF

Recent Articles
  1. The Changing Landscape of Multiple Myeloma Therapies Market
  2. Notizia
  3. The Promise of NK Cells: A Novel Approach to Immunotherapy
  4. BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 ...
  5. AZ offloads; Pfizer’s deal; Takeda’s work on plant; Germany’s doc payment
bispecific-antibodies-for-multiple-myeloma-treatment
Articles

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

pharma-news-for-gilead -otsuka-liquidia
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK’s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Abeona Secures FDA Nod for ZEVASKYN, the First Gene Therapy for RDEB; AbbVie Gains FDA Approval for RINVOQ in Giant Cell Arteritis; Lantern Pharma Advances LP-184 with IND Clearance for TNBC Trial; Ichnos Glenmark Earns FDA Fast Track for ISB 2001 in Multiple Myeloma; Rezolute Wins Breakthrough Therapy Designation for Ersodetug in Tumor-Induced Hypoglycemia

Multiple Myeloma
Multiple MYELOMA drugs Market.
Multiple Myeloma Market
Multiple Myeloma Pipeline
RBC
red blood cells
loader
loader